Insider buying last 90 days
No open-market insider purchases were filed for PCVX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Vaxcyte's shares climbed this week after the company announced positive topline OPUS-1 Phase 3 data for its VAX-31 pneumococcal vaccine candidate in adults, meeting all primary endpoints with a safety profile similar to existing vaccines. The move was reinforced by a Q3 report in which Vaxcyte topped EPS estimates, posting a loss of ($1.99) against a ($2.13) estimate, even as nine-month operating cash use topped $737 million and the net loss widened to $297.1 million from $212.8 million a year earlier. BTIG maintained a Buy rating with an $89.00 price target following the news.
Shares closed at $67.53, up 5.7%, sitting above both the 50-day average of $61.86 and the 200-day average of $57.45. The GekkoIndex reading of 53.7 places the stock in the Neutral zone, down 6.8 over the past five readings. Price remains 18.3% below Gekko Fair Value of $82.7, a gap that has widened rather than closed despite the week's rally.
The next earnings date falls on 23 February 2027, well outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality skews unfavorable, with the next 20 trading days averaging -1% over 5 years and rising in only 2 of them. Analyst sentiment remains heavily tilted toward Buy ratings, with a consensus target of $117.3 implying notable upside.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Vaxcyte scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Above 50 and 200-day
Close $63.37 is above the 50-day ($62.24) and 200-day ($57.70) averages, and the 50-day is above the 200-day.
See the chart57.1, Neutral
Reading 57.1 is in the Neutral zone.
See the GekkoIndex23.4% below
Price is 23.4% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings−2.5% on average
From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Vaxcyte closed at $63.37 on Nov 13, 2026, +37.5% over the past year, inside a 52-week range of $42.40 to $90.75.
Use the left and right arrow keys to read daily values.
Put PCVX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Vaxcyte works in early-stage biotechnology, focused on building protein-based vaccines aimed at preventing or treating bacterial infections. Its furthest-along program, VAX-24, is a 24-valent pneumococcal conjugate vaccine in Phase 1/2 testing meant to guard against invasive pneumococcal disease and pneumonia. The company is best recognized for this pneumococcal vaccine work within its broader research pipeline.
Alongside VAX-24, Vaxcyte is developing several other vaccine candidates. VAX-XP targets emerging bacterial strains and antimicrobial resistance, VAX-A1 is a conjugate vaccine aimed at Group A Streptococcus, and VAX-PG is designed against the bacterium linked to periodontitis. The company's activities center on advancing these candidates through clinical development rather than on selling approved products.
Vaxcyte was founded in 2013 under the name SutroVax, Inc., adopting its current name in May 2020. It is headquartered in San Carlos, California, and its shares trade on the NASDAQ under the ticker PCVX.
Vaxcyte’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.1, in the Neutral zone, up 0.7 points over five sessions.
Up 0.7 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +0.8% | −1.2% | ||
| Accumulation | 235 | −0.9% | −0.6% | ||
| Neutral (current zone) | 393 | +1.2% | +3.0% | ||
| Distribution | 32 | 0.0% | −0.2% | ||
| Selling | 7 | Too few readings yet | |||
Average PCVX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Vaxcyte trades 23.4% below Gekko Fair Value of $82.69, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Vaxcyte shares are worth, recalculated every trading day.
$82.69
Gekko Fair Value, Nov 14, 2026
23.4% Undervalued
At the end of Aug 2026 the price was 33.2% below the estimate.
No open-market insider purchases were filed for Vaxcyte, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for PCVX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in PCVX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold PCVX.
Vaxcyte reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 2 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$1.97 est −$2.06 | — est $12.50M | +7.7% |
| May 6, 2026 | −$2.30 est −$1.78 | — est $12.50M | −7.5% |
| Feb 24, 2026 | −$1.80 est −$1.53 | — est $18.75M | +4.6% |
| Nov 4, 2025 | −$1.56 est −$1.27 | — | −5.9% |
| Aug 6, 2025 | −$1.22 est −$1.12 | — | −11.0% |
| May 7, 2025 | −$1.04 est −$1.02 | — | +7.6% |
| Feb 25, 2025 | −$1.02 est −$0.99 | — | −3.7% |
| Nov 5, 2024 | −$0.83 est −$1.10 | — | −2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Vaxcyte is $116.40, +83.7% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | TD Cowen | $75 | +18.4% |
| Nov 5 | Leerink Partners | $102 | +61.0% |
| Nov 5 | Bank of America Securities | — | — |
| Nov 4 | BTIG | $89 | +40.4% |
| Oct 12 | Cantor Fitzgerald | $120 | +89.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Vaxcyte averaged −2.5% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −5.1% | 2 of 5 |
| Next 10 trading days | −5.7% | 2 of 5 |
| Next 15 trading days | −3.6% | 1 of 5 |
| Next 20 trading days | −2.5% | 2 of 5 |
| Next 30 trading days | +0.4% | 2 of 5 |
For scale, PCVX’s typical 20-trading-day move in either direction is about 8.7%.
Vaxcyte’s market cap is $10.03B and revenue of $0 over the last twelve months.
Coverage of Vaxcyte this week reads positive: 4 positive, 4 neutral and 1 negative headlines.
Vaxcyte’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Vaxcyte’s market cap is $10.03B at the Nov 13, 2026 close of $63.37, with 158.3M shares outstanding.
The consensus analyst 12-month price target for Vaxcyte is $116.40, +83.7% from the last close. Of the 10 firms that rated the stock in the last 90 days, 9 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Vaxcyte is undervalued: the Nov 13, 2026 close of $63.37 is 23.4% below Gekko Fair Value of $82.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Vaxcyte is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$1.92 per share on revenue of $12.50M. Vaxcyte beat the earnings estimate in 2 of its last 8 reports, moving 6.3% on average across the report.
Vaxcyte’s 52-week high is $90.75 and its 52-week low is $42.40; it closed at $63.37 on Nov 13, 2026, +37.5% over the past year. Over the last five years the shares peaked at $121.06 on Sep 19, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.